1. ALLA AKTIER
  2. NYHETER
  3. ONCOPEPTIDES

Oncopeptides

Nyheter Oncopeptides Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Oncopeptides publishes the 2025 Annual Report

REG

Stockholm – April 28, 2026 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that the 2025 Annual Report has been published.

“2025 was a year of progress for Oncopeptides. As we celebrated our 25th anniversary, we transitioned from a foundational launch phase into a period of growth, scientific validation, and strategic clarity,” says Sofia Heigis, CEO of Oncopeptides. “Our flagship drug, Pepaxti, is no longer just “newly launched”— it is a growing treatment delivering triple-digit growth and life-changing. The most exciting development of the year lies in our potential ability to deploy our validated PDC platform into new, high-value indications.”

The Annual Report for 2025 is available in PDF format at Oncopeptides’ web site under financial reports.

For more information, please contact:
David Augustsson, Director of IR and Communications, Oncopeptides AB (publ)
E-mail: ir@oncopeptides.com
Cell phone: +46 76 229 38 68

This information is information that Oncopeptides is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-04-28 17:30 CEST.

About Oncopeptides
Oncopeptides is a Swedish biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers. 

The company uses its proprietary Peptide Drug Conjugate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. Its flagship drug is currently being commercialized in Europe with partnership agreements for South Korea, the Middle East and Africa and elsewhere.

Oncopeptides is also developing several new compounds based on its two proprietary technology platforms PDC and SPiKE.

The company was founded in 2000, has about 80 employees with operations in Sweden, Germany, Austria, Spain and Italy. Oncopeptides is listed on Nasdaq Stockholm with the ticker ONCO.

For more information see: www.oncopeptides.com

Attachments
Annual Report 2025 260428 En
Press Release Annual Report 2025 En

Datum 2026-04-28, kl 17:30
Källa MFN
Bifogade filer
Annual Report 2025 260428 En
Press Release Annual Report 2025 En